Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Turlough Farnan
To examine the clinical data that has been published in telerobotic ENT-head and neck surgery, assess the value of current clinical applications, and pinpoint new development areas. The following keyword searches for papers were used to find them in PubMed, Medline, and the Cochrane Database: Telerobotic/Robotic ENT, Otorhinolaryngology, Head and Neck Surgery, Thyroid and Parathyroid Surgery. We omitted non-clinical review articles and preclinical investigations. Seven review articles were among the 45 publications that were located. 20 clinical trials have reported transoral robotic surgery (TORS), 13 have reported robotic-assisted thyroidectomy, 4 have reported Para thyroidectomy, and 1 has documented skull base surgery.
The majority of TORS papers deal with Stage III and IV oropharyngeal cancer. Improvements in swallowing function and the avoidance or dosage reduction of adjuvant chemotherapy and radiotherapy are clinical benefits. The absence of a neck scar is the main clinical benefit of robotic-assisted neck surgery. The robotic thyroidectomy learning curve is 50 cases. Body habitus is a crucial consideration when determining if robotic transoral and neck surgery is feasible. The use of robotic-assisted thyroidectomy, TORS, and Para thyroidectomy implies positive advancements in patient care. To evaluate clinical success, cost effectiveness, and patient benefit in the current applications, randomised control trials are required. The number of therapeutic applications that are currently viable in this field will increase as robotic technology continues to advance.